Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | LITAF | Q99732 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774918 | 0.85 | TNF (0.40) | TNFLITAFPTGS2HPGDEGLN1 | |
| SCHEMBL774356 | 0.77 | TNF (0.45) | TNFLITAF | |
| SCHEMBL2017495 | 0.73 | MEN1 (0.61) | KDM4EMEN1KMT2A | |
| SCHEMBL23925083 | 0.71 | PIN1 (0.45) | TNFLITAFKDM4EHPGDALDH1A1 | |
| SCHEMBL29989486 | 0.71 | PIN1 (0.45) | TNFLITAFKDM4EHPGDALDH1A1 | |
| SCHEMBL1257681 | 0.71 | EGLN1 (0.37) | PTGS2EGLN1F2R | |
| SCHEMBL437559 | 0.70 | HAVCR2 (0.40) | TNFLITAFKDM4EHPGDP2RX7 | |
| SCHEMBL29829215 | 0.68 | PDE4A (0.42) | TNFLITAFKDM4EHPGDALDH1A1 | |
| SCHEMBL23497102 | 0.68 | PDE4A (0.42) | TNFLITAFKDM4EHPGDALDH1A1 | |
| SCHEMBL27851350 | 0.68 | TNF (0.37) | TNFLITAFKDM4EP2RX7ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011022216-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HMOX2, HMOX1, MPO | TNF 413/4885LITAF 148/4885PTGS2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.